AB SCIENCE SA (AB.PA)
FR0010557264 - Common Stock
Overall AB gets a fundamental rating of 1 out of 10. We evaluated AB against 49 industry peers in the Pharmaceuticals industry. AB has a bad profitability rating. Also its financial health evaluation is rather negative. AB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year AB has reported negative net income.
AB had a negative operating cash flow in the past year.
AB had negative earnings in each of the past 5 years.
In the past 5 years AB always reported negative operating cash flow.
1.2 Ratios
AB has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AB has a better Gross Margin (96.76%) than 95.74% of its industry peers.
In the last couple of years the Gross Margin of AB has remained more or less at the same level.
AB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM | N/A | ||
| GM | 96.76% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.03%
GM growth 5Y0.79%
2. Health
2.1 Basic Checks
AB does not have a ROIC to compare to the WACC, probably because it is not profitable.
AB has less shares outstanding than it did 1 year ago.
AB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AB has a worse debt to assets ratio.
2.2 Solvency
AB has an Altman-Z score of -16.86. This is a bad value and indicates that AB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -16.86, AB is not doing good in the industry: 95.74% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.86 |
ROIC/WACCN/A
WACC7.16%
2.3 Liquidity
AB has a Current Ratio of 0.90. This is a bad value and indicates that AB is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.90, AB is not doing good in the industry: 80.85% of the companies in the same industry are doing better.
AB has a Quick Ratio of 0.90. This is a bad value and indicates that AB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.88, AB is in line with its industry, outperforming 42.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
AB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.63%.
Looking at the last year, AB shows a very negative growth in Revenue. The Revenue has decreased by -40.39% in the last year.
Measured over the past years, AB shows a very negative growth in Revenue. The Revenue has been decreasing by -11.24% on average per year.
EPS 1Y4.63%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q32.52%
Revenue growth 1Y-40.39%
Revenue growth 3Y-15.2%
Revenue growth 5Y-11.24%
Revenue growth Q2Q-58.3%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for AB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AB SCIENCE SA
EPA:AB (9/22/2023, 7:00:00 PM)
2.47
+0.01 (+0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap125.70M
Analysts84.44
Price Target10.2 (312.96%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 131.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.29
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.02
BVpS-0.7
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | 96.76% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.03%
GM growth 5Y0.79%
F-Score1
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 67.22% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | -16.86 |
F-Score1
WACC7.16%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)41.9%
Cap/Sales(5y)35.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y4.63%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q32.52%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue growth 1Y-40.39%
Revenue growth 3Y-15.2%
Revenue growth 5Y-11.24%
Revenue growth Q2Q-58.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.71%
OCF growth 3YN/A
OCF growth 5YN/A